Araceli Biosciences
↗Tigard, Oregon, United States
Araceli Biosciences is a biotechnology company focused on accelerating drug discovery through innovations in high-content imaging and AI-driven analysis. The company develops hardware and software platforms, such as the Endeavor® high-content imaging system and Clairvoyance AI-driven analysis software, designed to address bottlenecks in pharmaceutical research by providing faster, more precise, and actionable data.
Originally a spinout from Phoseon Technology, the company is headquartered in Tigard, Oregon. It serves the broader life sciences, pharmaceutical, and biotech sectors by enabling researchers to generate high-quality, analysis-ready data to improve candidate selection and reduce downstream failures in the drug development pipeline.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Life Science Tools & Services
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$11.2M
Investors:Bill Cortelyou (Lead Investor)
0
CORPORATE STRUCTURE
Key Partnerships:VALID Therapeutics (Collaboration to advance AI-driven drug discovery), Biosero (Integration of Endeavor platform into automated lab workflows)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Matt Beaudet - CEO
Shawn MacDonald - CFO
Jeffrey Harris - General Manager
Board Members:Bill Cortelyou (Chairman)
LINKS
Website:aracelibio.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Araceli Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Araceli Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.